This article is more than 5 years old. Information may no longer be current.

Integra LifeSciences acquires dural repair product lines from Covidien

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Integra LifeSciences Holdings Corporation has completed the acquisition of the DuraSeal product line from Covidien.

According to a company press release, Integra will provide complete 2014 guidance, including the financial impact of this acquisition, on its 2013 full year financial results conference call on Feb. 25.

“The acquisition of the DuraSeal product line offers us a great opportunity to drive our neurosurgery growth strategy, aimed at providing a broader set of solutions for surgical procedures in the head,” Robert Davis, president of Integra’s U.S. neurosurgery division. “The neurosurgery product portfolio will now have products in both dural grafting and the different indication of dural sealing. DuraSeal is the first-to-market dural sealant approved for use in both the cranium and spine.”